Search

Displaying results 1181 - 1190 of 7536 in total
  1. Drug

    (S)-camphor

    go.drugbank.com/drugs/DB11345
    Approved

    (S)-camphor is not the naturally-occurring stereoisomer but displays similar TRPV channel affinity and current inhibition [A33086]. … Camphor is a major active ingredient in over-the-counter balms and liniments supplied as topical analgesics by causing sensitization to heat and coolness to relieve minor muscle and joint pain [A33086]

  2. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo [L4166].

  3. Drug

    Mupirocin

    go.drugbank.com/drugs/DB00410
    ApprovedInvestigationalVet approved

    _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_. … [L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes

  4. Drug

    Ferrous sulfate anhydrous

    go.drugbank.com/drugs/DB13257
    ApprovedInvestigational

    [A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells.

    Mixtures: Formule No 204 Profil Tab
  5. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … blood and to various extracerebral tissues.

  6. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. … Tofacitinib is marketed under the brand name Xeljanz by Pfizer.

  7. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].

  8. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  9. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.

    Synonyms: INO
  10. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome